Monthly cabotegravir-rilpivirine injections superior to standard oral ART for HIV with adherence challenges

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) and medication adherence challenges, according to a study published online Feb. 18 in the New England Journal of Medicine.